H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on Audentes Therapeutics (BOLD) today and set a price target of $48.00. The company’s shares closed last Monday at $27.84.
According to TipRanks.com, Chattopadhyay is ranked 0 out of 5 stars with an average return of -11.6% and a 31.7% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Precision BioSciences Inc, and Voyager Therapeutics Inc.
Currently, the analyst consensus on Audentes Therapeutics is a Moderate Buy with an average price target of $39.75, a 42.6% upside from current levels. In a report released yesterday, Piper Jaffray also maintained a Buy rating on the stock with a $55.00 price target.
See today’s analyst top recommended stocks >>
Based on Audentes Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $44.76 million. In comparison, last year the company had a GAAP net loss of $36.29 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Audentes Therapeutics, Inc. is a biotechnology company, which engages on development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. Its products include AT001 for the treatment of X-Linked Myotubular Myopathy, AT002 for the treatment of Pompe disease, and AT003 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA.
